Tag
Antenatal oxytocin combined with dexamethasone significantly improves respiratory adaptation and reduces adverse outcomes in late-preterm lambs delivered by cesarean section, highlighting potential novel preventive strategies for neonatal r
The MAIA final analysis establishes daratumumab plus lenalidomide/dexamethasone as a superior frontline regimen, significantly extending median overall survival to 7.5 years in transplant-ineligible newly diagnosed multiple myeloma patients
A quadruple-blinded RCT found that oral dexamethasone given after pediatric tonsillectomy modestly reduced pain and substantially lowered opioid prescriptions, without increasing complications.
The Phase 3 DexEnceph trial found that adjunct dexamethasone is safe in adults with HSV encephalitis but does not significantly improve verbal memory scores at 26 weeks compared to aciclovir monotherapy, suggesting a need for earlier or mor
The IFM2017-03 phase 3 trial demonstrates that a dexamethasone-sparing regimen combining daratumumab with lenalidomide markedly improves progression-free survival in frail elderly multiple myeloma patients, without increasing serious advers
The REST trial demonstrated that combining isatuximab with weekly bortezomib, lenalidomide, and limited dexamethasone yields promising efficacy and manageable safety in older patients with transplant-ineligible multiple myeloma.
The EMN20 phase 3 trial demonstrates that adding carfilzomib to lenalidomide-dexamethasone significantly increases MRD negativity and progression-free survival in transplant-ineligible newly diagnosed multiple myeloma, with manageable toxic
Dexamethasone is a powerful corticosteroid that requires careful use due to potential harmful drug interactions and side effects. This article highlights crucial precautions and compatibility issues for safe administration.
